There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among k ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

You may soon be able to eat your Ozempic … sort of. GLP-1 supplements are booming, promising to deliver similar benefits to Ozempic and Wegovy without the pricey injections. The latest contender ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

Kidney transplant recipients with type 2 diabetes prescribed GLP-1 receptor agonists had 31% lower mortality vs. nonusers. GLP-1 receptor agonist use was associated with 49% lower incidence of ...

GLP-1 drugs, originally for type 2 diabetes, are increasingly used for weight loss, but they can worsen eating disorders. Rapid weight loss from these drugs can reinforce harmful eating behaviors ...

Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. Find out which stock just plummeted to the bottom of the ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

GLP-1 medications are changing the way we approach weight loss and chronic conditions. Dr. Nima Mowzoon of UBI Telehealth ...